In this enteric capsule with oil coating, powdered or granulous contents meant to fill the capsule is mixed with a dose of ester containing sesaminol triglucosides or coixenolide. With the feature that emulsification arises while ester containing Sesaminol Triglucosides or coixenolide is integrated with the bile in human body, so that the activity of pharmacological molecules can be prevented, the pharmacological molecules of the contents is able to be coated by ester, forming carriers which are the ester oil film protecting the pharmacological activity of small molecules and ensuring that they can be transported to the small intestine. In this way, the capsule will prevent the pharmacological molecules of the contests from being decomposed by gastric acid when the capsule passes through it. Before entering the small intestine, with the emulsification brought about by the combination of ester oil film and bile, the pharmacological molecules of the contents can remain active for the optimum pharmacological activity after their entrance into the small intestine, decomposition, emulsification, and transportation into the blood. The absorptivity of the capsule will be enhanced when it is consumed. As a consequence, chances that the consumption of the capsule with pharmacological molecules causes the irritation of stomach will be effectively reduced, and stomach health will be protected.一種油膜包覆腸溶劑型,其係取一劑量含有芝麻木質酚(芝麻素)或薏苡酯之酯質物,將一預備填充於劑型內為粉末或顆粒物質之內容物與該酯質物相混溶,藉由酯質物含有芝麻木質酚(芝麻素)或薏苡酯之酯質因子可與人體膽汁結合而乳化可保其內容物藥物分子活性之特性,使內容物之藥物分子受酯質物包覆形成載體供保護小分子藥活性輸送至小腸之酯質油膜層,令劑型通過胃酸崩解殼層後可保有內容物之藥物分子不被胃酸分解,且進入小腸前之酯質油膜層與膽汁結合乳化後,從中內容物之藥物分子得以保其活性狀態並可使藥物活性進入小腸消化道分解乳化後輸出人體血液中而達到最適化之狀態與提升劑型食用之吸收率,藉此達到食用藥分子劑型可有效減少刺激胃部與保護胃部健康之目的。10‧‧‧劑型11‧‧‧殼層12‧‧‧內容物121‧‧‧藥物分子122‧‧‧酯質油膜層13‧‧‧核心空間
